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Abstract
Purpose of Review
The purpose of this review is to discuss the available evidence and therapeutic
considerations for intravenous drug therapy for refractory chronic migraine.

Recent Findings
In carefully monitored settings, the inpatient administration of intravenous lidocaine and
ketamine can be successful in treating refractory chronic migraine.

Summary
Many patients with refractory chronic migraine have experienced treatment failure with
the Raskin Protocol. The use of aggressive inpatient infusion therapy consisting of intravenous
lidocaine or ketamine, along with other adjunctive medications, has become increasingly common
for these patients when all other treatments have failed. There is a clear need for prospective studies
in this population comprised of patients who have largely been excluded from other studies.

Introduction
Migraine is one of the most common disabling neurologic conditions. It is a complex
neuro-inflammatory disorder with a significant genetic basis and is clinically heterogenic in
disease severity and symptomatology [1]. In addition to rare monogenic forms of migraine,
genome wide association studies have identified 44 independent single nucleotide polymorphisms
associated with migraine risk [2]. The pathophysiology of migraine is complex and is characterized
by dysregulation of nociceptive and other sensory processing throughout many central and
peripheral modulatory neural structures and networks. This dysregulation is mediated by a variety
of neurotransmitters, neuropeptides, and inflammatory molecules [•3]. Variability in the
involvement of these etiological factors within individuals is likely a significant contributor to the
clinical heterogeneity seen in migraine, including the constellation of symptoms, severity of
disease, and response (or lack thereof) to treatments.
With an overall prevalence of about 15%, migraine affects over 1 billion people worldwide,
and is second on the list of diseases accounting for years lived with disability. In the USA, nearly
40 million children and adults have the disease, and it is the number one cause of years lived with
disability for persons aged 15-49 [4]. Migraine can be divided into episodic and chronic forms
based on monthly headache frequency cutoff of 15 days per month with at least 8 migraine days
per month [•5]. About one in ten patients with migraine have the far more disabling and costly
form, chronic migraine (CM), with a global prevalence estimated between 1-2% [6]. A subset of
the population of people with CM have extreme disability due to daily or even continuous
symptoms despite numerous treatment attempts.
While there is some disagreement on the precise definition of refractory chronic migraine
(rCM), most agree that disabling disease which is unresponsive to 2-4 classes of commonly used

preventive migraine medication qualifies [7]. This cutoff is somewhat arbitrary and may understate
the refractory degree of disease, as it is not uncommon for patients to have experienced treatment
failure with 20 – 30 preventive medications [8]. The strictest criteria proposed for rCM have come
from the European Headache Federation, which calls for treatment failure with agents from 8
classes of preventive medications including any newly developed therapies [9]. Clinically there is
no specific or consistent symptomatic distinction between CM and rCM, and risk factors for rCM
are not well established [1]. A major step needed to generate useful data in this population is to
establish a widely accepted set of diagnostic criteria. This group of patients are particularly
underserved in terms of applicable data from therapeutic trials to guide treatment. Historically,
most large randomized controlled trials exclude patients with a history of extensive medication
failures, and those who have daily or continuous pain. Trials using aggressive inpatient therapies,
including lidocaine and ketamine infusion, are notoriously hard to design ethically with an
appropriate control group, as administering a true placebo to such a refractory population would
be inappropriate. It is also challenging to blind patients adequately given the prominent and
characteristic psychomimetic side effects of ketamine. Thus, our current typical approach to
inpatient rCM treatment is largely guided by years of anecdotal experience and observational data.
There are a variety of clinical scenarios in which inpatient treatment for migraine is
indicated. In general, these include failure of outpatient management in the setting of status
migrainosus or CM with continuous pain and significant disability, intractable nausea or vomiting,
medication overuse headache (MOH), and significant medical or psychiatric comorbidities [10].
While dihydroergotamine (DHE) infusion may be administered safely as an outpatient, the
vasoconstrictive properties may make advanced age or cardiovascular comorbidities indications
for inpatient treatment for safety reasons [11, 12]. Inpatients can be monitored on telemetry, and

the physician may consult a cardiologist for co-management in patients with substantial risk
(Table 1). Continuous lidocaine infusions can only be administered safely in the inpatient setting.
Another complicating factor that may warrant inpatient treatment is the presence of comorbid pain
and headache disorders, including fibromyalgia, post-traumatic headache, new daily persistent
headache (NDPH), and others [•13].

Historical Background
For patients with rCM, aggressive interventions are often undertaken, including the use of
repetitive doses of intravenous (IV) medications. One of the earliest descriptions of such an
approach was detailed and studied by Dr. Neil Raskin, and has been dubbed “The Raskin
Protocol.” A number of “Modified Raskin Protocol” descriptions have followed this, along with
the additional use of adjunctive medications.
Raskin’s original description from the 1980s [14] detailed the use of repetitive doses of IV
DHE and metoclopramide every 8 hours compared to repetitive doses of IV diazepam every 8
hours for up to 2 days in patients with continuous rCM, many of whom had become dependent on
analgesics, opioids, ergots, butalbital, benzodiazepines, prednisone, or a combination of those
substances. The diazepam group received 10 mg every 8 hours. In the DHE group, the dose was
adjusted based on the presence of nausea and headache. A “test dose” of 0.5 mg was given initially
with 10 mg metoclopramide. If within 1 hour the headache abated or nausea was present, no further
doses of DHE were given for 8 hours. If nausea recurred with the second dose of DHE 0.5 mg plus
metoclopramide 10 mg, the dose was reduced to 0.3 mg. If after the first dose the headache
persisted but there was no nausea at 1 hour, another 0.5 mg of DHE was administered, and every
8 hours thereafter for 2 days, 1 mg DHE and 10 mg metoclopramide was given. This was followed

by outpatient use of DHE suppositories or injections, as well as propranolol and ergonovine for
patients not fully responding to treatment. While non-randomized and unblinded, both treatment
groups had similar baseline characteristics, and the DHE group fared far better than the diazepam
group, both in the short term and long term, for up to 24 months.
Subsequent to this report, further exploration of the use of repetitive doses of IV DHE for
longer periods of time and with alternative adjunctive medications was undertaken by numerous
clinicians and researchers [15]. Alternative neuroleptic medications, such as prochlorperazine,
promethazine, droperidol, chlorpromazine, and haloperidol were used instead of metoclopramide,
and adjunctive IV medications, such as ketorolac, valproic acid, magnesium, and corticosteroids
were also given. In addition, some began to favor scheduling additional “pretreatment” drugs to
mitigate side effects, such as utilizing diphenhydramine to prevent neuroleptic-induced akathisia
or dystonic reaction. The scientific evidence behind these historical therapies used for decades is
weak, owing to the aforementioned challenges of designing randomized, blinded, and controlled
studies, and studies using numerous simultaneous medications in a desperate patient population
for whom placebo treatment could be viewed as unethical. Still, the available data are promising,
and these approaches have been embraced broadly and are still used today, with high levels of
satisfaction from patients and clinicians alike.

Intravenous Lidocaine
Background and clinical uses
Lidocaine is a local anesthetic and antiarrhythmic originally developed in 1943 by Swedish
chemists Nils Löfgren and Bengt Lundquist [16]. Prior to its development, the existing lot of local
anesthetics were classified as aminoesters. Lidocaine was the first local anesthetic to be classified

as an aminoamide. Its rapid onset of action and ease of storage addressed many of the concerns
that limited the aminoester class of local anesthetics. The introduction of lidocaine sparked the
development of other aminoamides including prilocaine, mepivacaine, bupivacaine and
ropivacaine [17].
Since the 1980s, IV lidocaine has been used for the treatment of various chronic pain
conditions. Shortly thereafter, Rosner reported his observations on the efficacy of IV lidocaine in
the treatment of headaches [18]. In 1988, Maciewicz et. al. was the first group to evaluate the
effectiveness of a single bolus dose of IV lidocaine in patients with “vascular headaches” [19]. In
their study, a single injection of 100 mg lidocaine was found to produce a rapid, but transient
reduction in acute pain in 13 patients with migraine or cluster headache. The mechanism of
analgesia was believed to be related to local inhibition of the nociceptive trigeminal afferents that
are responsible for nociception [19].
Investigations into the therapeutic potential of IV lidocaine as a continuous infusion has
also been studied in various types of headache disorders. Overall, the strength of evidence is weak,
and further studies are necessary to confirm their findings.

Evidence for lidocaine in headache
One of the earliest investigations of IV lidocaine infusions was performed by Hand and
Stark in 2000 [20]. In their retrospective study, they evaluated 19 patients that received a total of
27 lidocaine infusions. In their study, 22 infusions were given to 18 patients with rebound headache
(now called MOH in the diagnostic criteria). The remaining 5 infusions were administered in 3
patients for status migrainosus. Of the 22 infusions for rebound headache, 15 infusions led to
successful resolution of headache pain. Partial resolution, which was defined as requiring

supplemental DHE, occurred in 3 cases. The remaining 4 infusions provided no relief in patients
with rebound headache. In the population of patients receiving lidocaine infusions for status
migrainosus, 4 of the 5 infusions successfully relieved the headache[20].
Stark expanded upon his earlier work [20], and in conjunction with Williams, performed a
retrospective review of 71 inpatients admitted for chronic daily headache associated with MOH
[21]. In their study, patients with MOH were administered 2 mg/min of an IV lidocaine infusion
over a period of 7 to 10 days. According to their protocol, patients were prohibited from taking
opioids. Non-steroidal anti-inflammatory drugs and paracetamol were administered as rescue
medications for patients with inadequate relief from the lidocaine infusion. A total of 66 patients
completed the full protocol, and 90% of patients reported an immediate improvement or resolution
of their symptoms. Sustained benefits were also observed for 71% of patients at 6 months;
headache was absent in 51% and improved in 20% [21].
In a separate retrospective analysis, Rosen et. al analyzed the use of IV lidocaine in 68
patients with chronic daily headache or chronic cluster headache [22]. Unlike the previously
described studies, the lidocaine infusion was titrated to a serum concentration of less than 5 µg/mL.
The duration of therapy ranged from 2 to 15 days (mean 8.5 days). Headache severity was
measured on an 11-point verbal rating scale, with a score of 0 indicating headache freedom and a
score of 10 indicating the worst possible headache. A mean 4-point reduction in headache intensity
(p < 0.001) was observed following IV lidocaine therapy. Complete (25.4%) or partial (57.1%)
resolution of headache symptoms occurred in a substantial proportion of patients. Interestingly,
serum lidocaine levels did not correlate with improvement [22]. Mexiletine, an oral sodium
channel antagonist with limited evidence for use in refractory headache prevention, may be

administered daily following successful inpatient infusion with lidocaine in attempt to prolong the
improvement achieved with hospitalization [23].

Mechanism of Action in Headache
Despite demonstrating analgesic efficacy for various acute and chronic pain states, the
exact mechanism in which IV lidocaine produces analgesia is not clear. Best known for its ability
to block voltage gated sodium channels (VGSCs), this is unlikely to be the mechanism for
headache relief. Lidocaine appears to interact with several other molecular targets, including
potassium channels, calcium channels, G-protein-coupled receptors, acetylcholine receptors,
gamma-aminobutyric acid receptors (GABA), serotonin receptors, N-methyl-D-aspartate
(NMDA) receptors, and toll-like receptors [24]. Many of these receptors are implicated in the
induction, maintenance, and modulation of chronic pain states. Serotonin and GABA receptors,
for example, are involved in the descending inhibition of pain [25]. Lidocaine’s interaction with
second messenger systems and cell-signaling cascades may explain the clinical effects that persist
well beyond its short plasma half-life of 90-120 minutes [24].
The analgesic benefits of lidocaine also may be mediated indirectly via its primary
metabolite, monoethylglycine (MEG) [26, 24]. Animal models suggest that MEG attenuates the
inflammatory pain response and indirectly regulates the extracellular glycine concentration via
competitive inhibition of the glycine transporter, GlyT1 [26]. Glycine is a major neurotransmitter
involved in the descending regulation of pain [25, 26].
An alternative explanation of lidocaine’s analgesic effects pertains to its anti-inflammatory
properties [24, 27]. Preclinical and clinical studies demonstrate that lidocaine attenuates the
neuroinflammatory response involved in the induction and maintenance of chronic pain states [28].

In summary, the anti-nociceptive mechanisms of IV lidocaine in headache are complex and
not well understood, but central mechanisms involved with the modulation of pain and other
neuroinflammatory processes are believed to be key.

Adverse Effects
The short half-life and favorable pharmacokinetic profile of IV lidocaine make it relatively
safe for continuous IV delivery [29, 30]. However, local anesthetic systemic toxicity (LAST) can
occur if plasma lidocaine concentrations exceed 5 μg/ml [29].

IV lidocaine preferentially

distributes to the organs with the greatest perfusion, such as the brain and heart [31]. This
distribution pattern explains why the adverse effects of LAST are central nervous system (CNS)
and cardiovascular (CV) in origin. Symptom severity ranges from mild CNS phenomena (perioral
numbness, metallic taste in the mouth, lightheadedness, and tinnitus) and mild CV manifestations
(hypertension and tachycardia) to complete CNS and CV collapse [32].
Adverse CV effects are much less common, but cardiac arrest was reported in a 52-yearold woman receiving IV lidocaine for intractable hemicrania continua [33]. In this case report, the
authors hypothesized that the concomitant use of sertraline and trazodone, which are competitive
inhibitors of the CYP3A4 enzyme, led to accumulation and a plasma lidocaine level of 16 µg/mL
[33]. Drug accumulation can also occur in patients with hepatic or renal insufficiency. Propranolol,
used commonly for migraine prevention, also can lead to inhibition of hepatic metabolism and
subsequently toxic lidocaine levels [34]. Frequent measurements of plasma lidocaine levels can be
performed to ensure plasma lidocaine levels remain within the therapeutic range of 2‐5 µg/mL
[29].

Subanesthetic Ketamine
Background and clinical uses
With the worsening of the opioid crisis during the COVID-19 pandemic [35],
pharmacological alternatives to opioids for acute and chronic pain are needed more than ever. One
of the agents that has received great attention is ketamine, perhaps best known as a dissociative
anesthetic agent. This description was initially used in the first report of ketamine in humans by
Domino et al in 1965 [36] and refers to the phenomenon that the frontal cortex is stimulated while
other areas, such as the thalamus, are suppressed, resulting in a “dissociation” between various
parts of the brain [37]. Ketamine is well known as a non-competitive antagonist of the NMDA
receptor, which is thought to be responsible for many of its effects in acute and chronic pain,
though multiple other mechanisms of action contribute [38]. For postoperative pain and in opioidtolerant patients undergoing surgery, ketamine has been recommended by national guidelines as
an adjunct to opioids to improve analgesia and reduce overall opioid consumption [39]. Ketamine
has been shown to produce short- and medium-term pain relief in complex regional pain syndrome
[40, 41], a chronic pain condition recently categorized as nociplastic pain [42]. Nociplastic pain
refers to disorders that involve altered pain processing but do not conform to the nociceptive pain
definition and lack a distinct nerve injury that would qualify them as neuropathic pain [43].

Evidence for ketamine in headache
Several studies that have evaluated ketamine’s effects in various headache conditions have
come from the emergency department (ED) setting, but few studies have focused on ketamine for
refractory headache. In one clinical trial that compared intranasal (IN) ketamine to IV
metoclopramide in patients presenting to the ED with a primary complaint of headache, IN

ketamine was not found to be superior to metoclopramide at 30 minutes after administration [44].
In another randomized controlled trial, a single infusion of 0.2 mg/kg of IV ketamine in the ED
did not reduce acute migraine symptoms compared to placebo [45]. In one review the authors
stated that “ketamine…does not provide substantial relief to migraine patients” [46]. However,
their claim was based on the results of two studies limited to acute migraine in the ED.
To the contrary, studies that have focused on patients with CM or more severe disease have
found mostly positive results. In a double-blind, randomized controlled trial, Afridi et al compared
IN ketamine to IN midazolam for migraine with prolonged aura and found that ketamine reduced
the severity of the aura [47]. One small case series of 6 patients with rCM reported short-term
relief after a continuous multi-day ketamine infusion [48]. A retrospective study of 77 patients
with CM or NDPH concluded that 71.4% of patients with refractory headache reported short-term
response after a multi-day continuous ketamine infusion, though the sustained response was not
statistically significant [49]. A subsequent study from the same institution that included 61 patients
with refractory headache reported that 77% were short-term responders after a 5-day ketamine
infusion, with less than half maintaining that level of relief at 1 and 3 months [13]. Possible
explanations for the inconsistent results in acute versus refractory migraine are discussed in the
next section.

Mechanism of Action in Headache
While the involvement of the NMDA receptor in ketamine’s anesthetic and acute pain
action is established [38], the positive results observed in studies in CM may point to the
involvement of additional mechanisms of action. Studies performed in the ED have used a single,
low-dose infusion and assessed analgesia almost immediately after the infusion. In the ED, where

preventing unnecessary hospital admissions is an important goal and short-term analgesia is the
focus, ketamine appears to provide minimal benefit in the acute setting [46]. However, in CM,
where symptoms are more frequent and disabling [5], the goal of treatment is often improving
quality of life and functionality over the long term and “breaking the cycle” of continual pain. In
the studies analyzed above that included patients with CM, longer infusions at greater doses were
used to achieve better results. In the study by Schwenk et al [13] the mean maximum ketamine
infusion rate was 0.76 mg/kg per hour, which is substantially higher than the doses used in the ED
studies [44, 45], and more importantly, the infusions were continued for 5 days. Sustained relief
was achieved in some of the patients, although these findings should be interpreted cautiously
given the lack of a standardized post-discharge medication regimen. Guidelines on the use of
ketamine infusions for chronic pain from the American Society of Regional Anesthesia and Pain
Medicine state that duration of clinical benefit has been associated with the total ketamine dose
administered [38], which is consistent with the findings observed in headache patients as well.
One possible explanation for the positive results seen in CM with ketamine is that during
longer infusions, the plasma levels of key ketamine metabolites accumulate and might contribute
to analgesia. In particular, (2R,6R)-hydroxynorketamine has been shown to be the predominant
metabolite after 3 days of continuous ketamine in a patient with complex regional pain syndrome
[50]. (2R,6R)-hydroxynorketamine has exhibited analgesic properties in a preclinical study in
several models of pain [51]. While larger studies in humans are clearly needed, and no definitive
statements can be made, these findings together raise the possibility that in certain chronic disease
states such as rCM, the benefits are greatest when ketamine infusions are given for several days at
a time at the highest doses tolerated.

One additional possibility worth noting is that ketamine could be exerting antiinflammatory effects in rCM. Modern hypotheses about the pathophysiology of migraine include
the assumption that neurogenic inflammation contributes to symptoms [52]. This assumption has
partially provided the basis for the introduction of the calcitonin gene-related peptide inhibitors as
a novel class of migraine drugs [53]. One study in treatment-resistant depression examined the
correlation between the antidepressant effect of a low-dose ketamine infusion and proinflammatory markers, including C-reactive protein, interleukin-6, and tumor necrosis factoralpha, and found that ketamine was associated with a reduction in cytokine levels [54]. However,
studies examining ketamine’s effects on inflammatory markers in depression have been
inconsistent overall [55], and while some authors have suggested it could reduce inflammation in
painful states [56], the clinical correlates of these hypotheses are lacking.

Exploring novel ketamine mechanisms
Ketamine use has been shown to result in neuroplasticity and neurogenesis, demonstrating
lasting structural and functional neurological changes. Ketamine use in treatment-resistant
depression resulted in rapid changes in white matter diffusivity and microstructure [57]. In this
population, a single dose of ketamine has been shown to produce rapid relief of symptoms that
lasts up to 2 weeks [58]. Another rapid effect observed from ketamine administration is induction
of hippocampal neuron maturation [59]. Ketamine has been shown to increase brain-derived
neurotrophic factor resulting in functional connectivity changes within the brain [60]. Ketamine
may also exert antinociceptive activity through direct activity on μ- and δ-opioid receptors and by
induction of endogenous opioid synthesis [61]. Finally, in addition to NMDA receptor activity,
ketamine’s antinociceptive effect is associated with increased α-amino-3-hydroxy-5-methyl-4-

isoxazolepropionic acid receptor (also known as AMPAR) activity and enhanced serotonergic
neurotransmission [62].
At this time, definitive anti-nociceptive mechanisms of ketamine are not fully established,
and the primary mechanisms at play in patients with migraine remains speculative. Future studies
will be required to further elucidate this.

Adverse Effects
Ketamine is associated with a variety of adverse effects, most of which have been reported
as mild in clinical studies but which can require adjustment in infusion rate or treatment with
adjunctive medications. One meta-analysis of subanesthetic perioperative ketamine found that the
incidence of psychomimetic effects (hallucinations, psychiatric disturbances, unpleasant dreams,
diplopia, blurred vision, nystagmus, or dysphoria) was increased in patients who received ketamine
versus control groups [63], while another found that psychomimetic effects were equal in ketamine
and control groups [64]. However, when looking specifically at patients receiving ketamine for
headache, one report noted that hallucinations occurred in 28% of patients, vivid dreams in 13%,
blurry vision in 38%, and nausea and vomiting in 38% [13]. In that study, the mean maximum
ketamine infusion rate was 0.76 mg/kg per hour and all patients received a clonidine patch to
mitigate adverse effects. Clonidine is also useful in mitigating the sympathomimetic effects of
ketamine such as hypertension [65], as well as insomnia and agitation. The authors reported that
60 of the 61 patients completed their 5-day treatment course with 1 patient electing to stop because
of adverse effects. These results are somewhat difficult to interpret because patients with CM often
report nausea and vomiting as part of their clinical syndrome, [66] and patients in this study were
also given neuroleptic medications that could have caused some of the psychomimetic effects. For

patients with psychiatric comorbidities, such as depression, post-traumatic stress disorder, bipolar
disorder, dissociative disorders, or suicidal ideation, co-management with a psychiatrist should be
considered. In general, ketamine’s adverse effects occur when infusions are given for prolonged
periods of time and at higher doses. Mitigating medications, such as clonidine [67] and
benzodiazepines [68], can help reduce duration and severity of these effects but cannot fully
prevent them.
Ketamine use, especially chronic abuse, may result in end organ damage, including liver
and bladder toxicity. Ketamine-induced cystitis is thought to occur due to direct toxicity and
induction of apoptosis in urothelial cells [69]. Papillary necrosis can lead to ureteral obstruction,
urinary retention, and hemorrhagic cystitis [70]. Patients should be monitored for the development
of urinary symptoms. National guidelines for the use of ketamine have recommended that
ketamine be avoided in patients with severe liver disease and used cautiously in patients with
moderate disease [38]. Furthermore, the guidelines state that liver toxicity most commonly
presents as elevated liver transaminases and mostly has been observed in ketamine abusers.
However, a subsequent report of 115 patients with rCM and complex regional pain syndrome
found that patients were more likely to have developed elevated transaminases during a repeat
ketamine infusion than their initial infusion [71], so caution is warranted even with medically
supervised ketamine infusions, and consideration of liver function tests should be given when
high-dose or multi-day infusions are planned.
A variety of concerns about potentially deleterious effects of ketamine stem from data in
patients chronically abusing the drug. Studies have identified long-term effects, including focal
decrease in brain connectivity, focal decrease in cortical volumes, impairment within certain
cognitive domains, and white matter changes [72-74]. However, there are several confounding

variables in these studies, and it is not possible to establish causality or implications of the findings
from this relatively weak evidence. Large controlled longitudinal studies are required to further
evaluate the long-term effects of ketamine.

Table 1. Inpatient infusions for patients with refractory chronic migraine
Drug

Dosing Range

Dihydroergotamine

0.1 – 1 mg Q8H
SCH

Ketamine

0.1 – 1 mg/kg/h
continuous

Lidocaine

0.6 – 4 mg/min
continuous

Adverse Effects
Nausea/vomiting,
hypertension,
flushing, diarrhea,
chest pain, leg
cramps
Hallucinations,
nausea/vomiting,
sedation, vivid
dreams
Sedation,
nausea/vomiting,
cardiac
dysrhythmias, vivid
dreams,
hallucinations

Contraindications
Pregnancy,
uncontrolled
hypertension, any
active vascular disease
Pregnancy, active
psychosis, liver
disease, uncontrolled
cardiac disease
Certain cardiac rhythm
abnormalities such as
heart block or
conduction delays

Conclusion
Migraine remains tremendously burdensome, especially for the small yet substantial
proportion of patients with extremely refractory disease. For nearly 30 years, dedicated advanced
treatment approaches have been explored with a goal of providing meaningful relief. Despite
advances to date, there remain far too many patients who continue to experience treatment failure
from very aggressive, and in some cases risky, combination approaches. Most, if not all, patients
with rCM have experienced failure with the Raskin protocol when used without the
coadministration of multiple other infusions. Thus, a modified, multiday, aggressive inpatient
infusion approach has become increasingly common for rCM and incorporates a variety of other

medications, including coadministration with continuous lidocaine or ketamine infusions in a
closely monitored setting to mitigate serious adverse events. A widely accepted standardized set
of criteria for rCM diagnosis is needed to further explore the unique demographics,
pathophysiological mechanisms, risk factors, and prognostic factors for rCM. This will facilitate
the future research that is required to identify more effective, safe, and tailored therapeutic
approaches to better complement a holistic, multidisciplinary plan of care.
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